Skip to main content
Top
Published in: Digestive Diseases and Sciences 2/2009

01-02-2009 | Case Report

Severe Hepatotoxicity Due to Hydroxycut: A Case Report

Authors: Michael Shim, Sammy Saab

Published in: Digestive Diseases and Sciences | Issue 2/2009

Login to get access

Excerpt

A 28-year-old male was transferred to our institution with 3 weeks of fatigue, dyspnea on exertion, jaundice, and dark urine. In an effort to lose weight, he had been taking Hydroxycut, two tablets, two to three times per day (which is within the manufacturer’s suggested dosing), from 3 months prior to admission up until the development of symptoms. Additionally, for soreness associated with his aerobic exercise program, he took an over-the-counter pain-reliever containing acetaminophen 250 mg, aspirin 250 mg, and caffeine 65 mg, four tablets per day for the 10 days leading up to the development of his symptoms. He was not a heavy drinker of ethanol, drinking 2–3 beers per week. Physical examination was unremarkable and without stigmata of chronic liver disease. Laboratory analysis revealed a serum aspartate aminotransferase of 1049 U/l (normal range 7–36 U/l), alanine aminotransferase of 2272 (normal 4–45 U/l), alkaline phosphatase of 152 U/l (normal 31–103 U/l), total bilirubin of 18.1 mg/dl (normal 0.2–1.1 mg/dl), conjugated bilirubin of 9.0 (normal 0.0–0.2 mg/dl), albumin level of 4 g/dl (normal 3.7–5.1 g/dl), prothrombin time of 12.8 s (normal 9.2–10.6 s), normal complete blood count, normal electrolyte panel, and normal estimated glomerular filtration rate. Aminotransferase levels and prothrombin time began to decline immediately after admission and bilirubin peaked on hospital day 2 at 22.4 mg/dl. Acetaminophen level was undetectable. Tests for viral hepatitis were negative. Ferritin was markedly elevated at 9519 ng/ml (normal 10–210 ng/ml). HFE genotyping was negative for H63D or C282Y mutations. Antinuclear antibody titer was 1:40 (normal, <1:40), smooth muscle antibody titer was 1:20 (normal, <1:20), liver kidney microsomal antibody was negative, and soluble liver antigen antibody was negative. Serum copper level was 96 mcg/dl (normal 70–140 mcg/dl) and ceruloplasmin was 31 mg/dl (normal 18–54 mg/dl). Twenty-four hour urine copper level was 290 mcg/dl (normal 3–50 mcg/dl). Slit-lamp examination for Kaiser-Fleischer rings was equivocal. Abdominal ultrasound with Doppler and computed tomography (CT) scan with intravenous contrast were both normal. The patient’s liver function tests continued to improve and he was discharged on hospital day 9. …
Literature
1.
go back to reference Stevens T, Qadri A, Zin NN (2005) Two patients with acute liver injury associated with use of the herbal weight-loss supplement Hydroxycut. Ann Intern Med 142(6):477–478PubMed Stevens T, Qadri A, Zin NN (2005) Two patients with acute liver injury associated with use of the herbal weight-loss supplement Hydroxycut. Ann Intern Med 142(6):477–478PubMed
4.
go back to reference Bonkovsky HL (2005) Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 144(1):68–71 Bonkovsky HL (2005) Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 144(1):68–71
5.
6.
go back to reference Garcia-Moran S, Saez-Royuela F, Gento E, Lopez Morante A, Arias L (2004) Acute hepatitis associated with Camellia thea and Orthosiphon stamineus ingestion. Gastroenterol Hepatol 27:559–560. doi:10.1157/13068145 PubMedCrossRef Garcia-Moran S, Saez-Royuela F, Gento E, Lopez Morante A, Arias L (2004) Acute hepatitis associated with Camellia thea and Orthosiphon stamineus ingestion. Gastroenterol Hepatol 27:559–560. doi:10.​1157/​13068145 PubMedCrossRef
7.
go back to reference Thiolet C, Mennecier D, Bredin C, Moulin O, Rimlinger H, Nizou C et al (2002) Acute cytolysis induced by Chinese tea. Gastroenterol Clin Biol 26:939–940PubMed Thiolet C, Mennecier D, Bredin C, Moulin O, Rimlinger H, Nizou C et al (2002) Acute cytolysis induced by Chinese tea. Gastroenterol Clin Biol 26:939–940PubMed
8.
go back to reference Vial T, Bernard G, Lewden B, Dumortier J, Descotes J (2003) Acute hepatitis due to exolise, a Camellia sinensis-derived drug. Gastroenterol Clin Biol 27:1166–1167PubMed Vial T, Bernard G, Lewden B, Dumortier J, Descotes J (2003) Acute hepatitis due to exolise, a Camellia sinensis-derived drug. Gastroenterol Clin Biol 27:1166–1167PubMed
10.
go back to reference Abu el Wafa Y, Benavente Fernández A, Talavera Fabuel A, Pérez Ramos MA, Ramos-Clemente JI (2005) Acute hepatitis induced by Camellia sinensis (green tea). Med Intern 22(6):298 Abu el Wafa Y, Benavente Fernández A, Talavera Fabuel A, Pérez Ramos MA, Ramos-Clemente JI (2005) Acute hepatitis induced by Camellia sinensis (green tea). Med Intern 22(6):298
11.
12.
13.
go back to reference Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY et al (2006) Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 12:1892–1895. doi:10.1002/lt.21021 PubMedCrossRef Molinari M, Watt KD, Kruszyna T, Nelson R, Walsh M, Huang WY et al (2006) Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 12:1892–1895. doi:10.​1002/​lt.​21021 PubMedCrossRef
Metadata
Title
Severe Hepatotoxicity Due to Hydroxycut: A Case Report
Authors
Michael Shim
Sammy Saab
Publication date
01-02-2009
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 2/2009
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-008-0353-4

Other articles of this Issue 2/2009

Digestive Diseases and Sciences 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine